Sign In
Buy IMMP
$0.451
+0.0315 (+7.52%)
At Close: Jul 13, 2026
Immutep Activities Report
01:00pm, Wednesday, 29'th Jan 2020
First progression-free survival (“PFS”) data expected from late-stage Phase IIb metastatic breast cancer study, AIPAC, in March 2020More mature data expected from TACTI-002 in.
Analysts Offer Insights on Healthcare Companies: Immutep (NASDAQ: IMMP) and Sintx Technologies (NASDAQ: SINT)
12:35pm, Saturday, 11'th Jan 2020
Analysts have been eager to weigh in on the Healthcare sector with new ratings on Immutep (IMMP – Research Report)
